


D6  
54(3)

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: <b>C07K 7/23, A61K 38/09, A61P 19/10</b>	A1	(11) International Publication Number: <b>WO 00/24764</b> (43) International Publication Date: <b>4 May 2000 (04.05.00)</b>
(21) International Application Number: <b>PCT/GB99/03553</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: <b>27 October 1999 (27.10.99)</b>		
(30) Priority Data: <b>9823515.3 27 October 1998 (27.10.98) GB</b>		
(71) Applicant (for all designated States except US): <b>FERRING BV [NL/NL]; Polaris Avenue 144, NL-2132 JX Hoofddorp (NL).</b>		
(72) Inventors; and		
(75) Inventors/Applicants (for US only): <b>AKINSANYA, Karen [GB/GB]; 38 Macnaghten Road, Bitterne Park, Southampton SO18 1GJ (GB). HAYWARD, Amanda [GB/GB]; 15 Chesterton Hall Crescent, Cambridge CB4 1AW (GB). QI, Steve [GB/GB]; 69 Downscroft Gardens, Hedge End, Southampton SO30 4RS (GB).</b>		Published With international search report.
(74) Agent: <b>GEERING, Keith, Edwin; Reddie &amp; Grose, 16 Theobalds Road, London WC1X 8PL (GB).</b>		

(54) Title: LHRH ANALOGUES FOR THE TREATMENT OF OSTEOPOROSIS



## (57) Abstract

A pharmaceutical composition for the treatment of osteoporosis and other disorders of bone growth is disclosed, which composition comprises a peptide according to the sequence (6): pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub> or an analogue thereof.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

## LHRH ANALOGUES FOR THE TREATMENT OF OSTEOPOROSIS

## FIELD OF INVENTION

The present invention relates to pharmaceutical compositions for the treatment of osteoporosis and other disorders of bone metabolism.

## BACKGROUND TO THE INVENTION

## i) Osteoporosis

Osteoporosis is a disease that affects many elderly people. Post-menopausal osteoporosis associated with oestrogen deficiency is the most common bone disease in the western world (Melton, J. Bone Miner. Res. 10 174-177, 1995). The basic mechanism underlying osteoporosis is when bone resorption exceeds bone formation resulting in net bone loss and an increase in the incidence of fractures. The dynamic processes that control bone morphogenesis take place in bone and bone marrow. Bone is a hard calcified connective tissue consisting of osteoprogenitor cells, osteoblasts, osteocytes and osteoclasts. Bone marrow is composed of haematopoietic stem cells and mesenchymal cells. These cells include osteoprogenitors, chondrocytes, adipocytes, fibroblasts and reticular cells. Bone metabolism and remodelling is dependent on a balance between two processes; bone resorption is dependent on osteoclast activity and bone formation is dependent on osteoblast activity. Osteoblast precursors are fibroblast-like, proliferating progenitor cells, which differentiate into osteoblasts that synthesise and deposit matrix to become new bone. Osteoclasts are a tissue specific subtype of macrophages responsible for resorption of bone. Mononuclear phagocytes from bone marrow fuse to form the large multinucleated osteoclasts. Osteoclastogenesis is a complex phenomenon that is facilitated by the interaction of bone marrow stromal cells with haematopoietic osteoclast precursors (Suda *et al.*, Endocr. Rev. 13 66-80, 1992).

A number of factors regulate the proliferation and differentiation of osteoblasts and osteoclasts including cell-cell interactions, cytokines, growth factors, steroid hormones and neurohormones. These factors act via endocrine, autocrine and paracrine mechanisms. Parathyroid hormone (PTH) is a key systemic regulator of calcium and bone metabolism acting principally by regulating bone resorption. There is evidence to suggest that PTH, vitamin D and calcitonin actions may be mediated by local factors found in bone (Oursler *et al.*,

Endocrinol. 129 3313-3320, 1990). A number of growth factors have been implicated such as insulin-like growth factors (IGF-I and IGF-II), fibroblast growth factors  $\beta$ FGF and aFGF (Baylink *et al.*, J. Bone Mineral Res. 8 (Supp. 2) S565-S572, 1993). Identification of locally produced agents that influence the process of bone formation and bone resorption may provide alternatives to current treatments for osteoporosis which include salmon calcitonin and hormone (oestrogen and progesterone) replacement therapy (Lindsay *et al.*, Lancet 341 801-805, 1993).

### ii) GnRH-II

Studies on the physiology of the hypothalamic-pituitary-gonadal axis have resulted in the recognition of gonadotropin releasing hormone (GnRH, otherwise known as luteinizing hormone releasing hormone, LHRH) as a key regulatory hormone. GnRH is released by the hypothalamus and acts on the pituitary to stimulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). More recently, a peptide related to GnRH has been identified, first in chickens (Miyamoto, US Patent No. 4,540,513) and subsequently in humans (White *et al.*, Proc. Natl. Acad. Sci. USA 95 305-309, 1998). This peptide has been called GnRH-II. The sequences of the two peptides are compared below.

GnRH      pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH<sub>2</sub>      (5)

GnRH-II    pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub>      (6)

Analogues have also been reported (Volkers *et al.*, US Patent No. 4,721,775). No clear evidence for a physiological role for GnRH-II has so far been presented.

### SUMMARY OF THE INVENTION

We have now found that GnRH-II is capable of modulating the differentiation of bone precursor cells and inducing the expansion of osteoblast populations. Accordingly, it is an object of the present invention to provide a pharmaceutical composition for the treatment of osteoporosis, which composition is characterised by the inclusion of GnRH-II or an analogue thereof. More specifically, the composition includes a peptide according to the sequence

pyroGlu-His-Trp-Ser-Xaa<sup>1</sup>-Gly-Xaa<sup>2</sup>-Xaa<sup>3</sup>-Pro-Gly-NH<sub>2</sub>      (7)

wherein       $\text{Xaa}^1$  is His or Tyr,  
                   $\text{Xaa}^2$  is Trp or Leu, and  
                   $\text{Xaa}^3$  is Tyr or Arg,

provided that when  $\text{Xaa}^1$  is Tyr and  $\text{Xaa}^2$  is Leu, then  $\text{Xaa}^3$  is not Arg. The invention further comprises a method for the preparation of such a composition, wherein the active peptide is combined with pharmaceutically acceptable excipients, and a method of treatment of osteoporosis, which is the administration to an individual in need of such treatment a therapeutically effective amount of the composition.

#### DESCRIPTION OF THE FIGURE

Figure 1 shows the effect of increasing doses of GnRH-II on serum calcium concentrations in ovariectomised rats.

#### DESCRIPTION OF THE INVENTION

As used herein, abbreviations referring to amino acids have their conventional meanings and indicate the natural L-isomer (except for the achiral amino acid glycine).

In a first embodiment, the invention as disclosed herein comprises a pharmaceutical composition for increasing bone mass or bone density, or for accelerating bone growth or repair. Preferably, the invention as disclosed herein comprises a pharmaceutical composition for the treatment of osteoporosis (including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis). The composition is characterised in that it includes as an active principal a peptide according to the sequence



wherein  $\text{Xaa}^1$  is either His or Tyr,  $\text{Xaa}^2$  is either Trp or Leu, and  $\text{Xaa}^3$  is either Tyr or Arg, provided that when  $\text{Xaa}^1$  is Tyr and  $\text{Xaa}^2$  is Leu, then  $\text{Xaa}^3$  is not Arg. Preferably,  $\text{Xaa}^1$  is His,  $\text{Xaa}^2$  is Trp, and  $\text{Xaa}^3$  is Tyr. It will be recognised that such a peptide can form salts

with acids (for example, acetic acid, trifluoroacetic acid, benzoic acid, hydrochloric acid, phosphoric acid and the like). To the extent that such salts are formed with pharmaceutically acceptable acids, they are included within the scope of the invention.

It will be understood by those familiar with the art that the composition will also comprise one or more excipients, such as diluents, carriers, preservatives, and the like. The composition may be a solid or liquid formulation, and will be appropriate for the intended route of administration. For example, the composition might be formulated as a tablet or capsule for oral administration, or as a suppository for rectal or vaginal use. Equally, the composition might be formulated as a solution, for example in isotonic saline, for intravenous administration. The composition may also be presented as a kit for formulation immediately prior to administration, for example as a freeze-dried powder in a sealed ampoule supplied with a second ampoule containing a solvent such as saline.

The composition may be used in clinical situations other than for the treatment of osteoporosis, where bone mass or bone density are reduced, or where bone growth or repair needs to be accelerated. Such situations include (but are not limited to) the treatment of osteogenesis imperfecta and osteomalacia, the prevention of bone loss when an individual is immobilised for an extended period, bone segmental defects, periodontal disease, metastatic bone disease, osteolytic bone disease, other conditions requiring healing or regeneration of cartilage defects or injury, facial reconstruction procedures, and the facilitation of healing following a fracture. The compounds of the present invention may also be used in conjunction with agents that affect bone resorption, for example antiresorptive agents, such as estrogen, bisphosphonates and calcitonin. In addition, or alternatively, the compounds of the present invention may modulate calcium metabolism, cell proliferation and/or differentiation of normal or aberrant cells or tissues involved in bone physiology.

In a second embodiment, the invention disclosed herein comprises a method for the preparation of a pharmaceutical composition for the treatment of osteoporosis (including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis) or another disorder, which method comprises the mixing of a peptide according to the sequence



wherein  $\text{Xaa}^1$ ,  $\text{Xaa}^2$  and  $\text{Xaa}^3$  are as defined above, with one or more pharmaceutically acceptable excipients. In the context of this invention, mixing is taken to include the blending together of solids, the dissolution of one or more solids in a liquid, and the dispersion of a solid in a liquid. The method may also include such processes as freeze-drying and microencapsulation necessary to obtain the formulation to be presented. Such processes as are known in the art are included within the scope of the present invention.

In a third embodiment, the invention as disclosed herein comprises a method for the treatment of an individual suffering from osteoporosis (including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis) or another bone disorder, or considered to be at risk of so suffering. This method of treatment comprises the administration to said individual of a therapeutically effective amount of a composition containing, as an active principal, a peptide according to the sequence



wherein  $\text{Xaa}^1$ ,  $\text{Xaa}^2$  and  $\text{Xaa}^3$  are as defined above. The method of treatment may comprise a single administration of the composition, but is more likely to comprise a course of repeated administrations. The frequency of the administrations may be from once per month to four times per day. The amount of active peptide in each dose will depend on the dosing schedule and the route of administration. Generally, it will be between one microgram (1 $\mu\text{g}$ ) and one hundred milligrams (100mg). Doses in the range 1-100 $\mu\text{g}$  are preferred when the composition is administered by intravenous injection. Doses in the range 10 $\mu\text{g}$  - 10mg are preferred when the composition is administered as slow-release

depots. Doses in the range 1-100mg are preferred when the composition is administered orally. Furthermore, high doses and frequent administration will be preferred when the desired outcome is to increase bone mass while lower doses and less frequent administration are more suited to the maintenance of bone mass.

The peptides that comprise the active agents of the compositions of the present invention can be prepared by the methods generally known in the art. For example, the peptides may be prepared by solid-phase synthesis. This involves the sequential addition of amino acid residues to a resin-bound intermediate according to the following strategy:

1. Formation of resin-bound first intermediate



Aaa = amino acid

PG = protecting group

FG = functional group

Res = polymeric resin

L = linker group ( -O- or -NH- )


2. Deprotection




3. Chain extension



4. Repeat steps 2 and 3 as necessary



5. Cleave/deprotect



In step one, a protected amino acid is reacted with a functionalised resin. The protecting group (PG) is most commonly *tert*-butyloxycarbonyl (Boc) or 9-fluorenylmethyloxycarbonyl (Fmoc). The functional group on the resin (FG) is commonly a chloroalkyl group, a hydroxyl group or an amine group. When FG is a chloroalkyl or hydroxyl group, the linker group (L) is an oxygen atom ( -O- ). When FG is an amine group, L is -NH-.

In step two, the protecting group (PG) is removed from the  $\alpha$ -amino group. When PG is Boc, this can be accomplished by treating the resin with acids such as trifluoroacetic acid or hydrogen chloride in dichloromethane. When PG is Fmoc, the deprotection can be accomplished by treating the resin with bases such as piperidine.

In step three, the peptide chain is extended by one amino acid residue. A protected amino acid is coupled to the amine group liberated in step two. Many reagents are known in the art for achieving this conversion. One combination is dicyclohexylcarbodiimide (DCC) and hydroxybenzotriazole (HOBr). Generally, a base will also be necessary. Suitable bases include triethylamine and N,N-diisopropylethylamine. The solvent will generally be dichloromethane, dimethylformamide, or a mixture of these.

If the side chains of the amino acids (Aaa - Nnn) contain reactive groups (for example amino groups, carboxylic acid groups, hydroxyl groups) then these will need protecting. The protecting groups chosen for the side chains are generally those that are stable under the conditions required to remove the protecting group (PG) from the  $\alpha$ -amino group. If PG is Fmoc, then the side chain protecting groups can conveniently be based on tert-butyl chemistry. On the other hand, if PG is Boc, then the side chain protecting groups can be based on fluorenylmethyl chemistry. Other protecting groups known in the art can also be used.

In step four, the deprotection/chain extension cycle is repeated until the desired peptide sequence has been constructed.

In step five, the completed peptide is liberated from the resin. Protecting groups are removed from the side chains either before or after the cleavage. When L is -NH-, the peptide liberated is in the form of the C-terminal amide. When L is -O-, the peptide liberated is often the C-terminal free acid and a second step is required to form the C-terminal amide.

The peptides may also be prepared by solution-phase synthesis, and this may be more convenient when large quantities of material are needed.

The above general description is further elaborated below in a number of examples. These are intended to illustrate certain aspects of the invention. They are not intended to be limiting in any way.

## EXAMPLES

### Example 1 - Synthesis of GnRH-II

#### 1A. Preparation of resin-bound protected peptide.

pyroGlu-His(Bom)-Trp(CHO)-Ser(Bzl)-His(Bom)-Gly-Trp(CHO)-Tyr(Bzl)-Pro-Gly- ORes

This peptide was prepared using standard solid-phase methods starting from Boc-Gly-esterified Merrifield resin (60 g, 1 mmol/g). The synthesis was performed in a manual synthesizer, with a total solvent and reagent volume of 300 mL for each operation. The standard deprotection/wash/coupling protocol is summarised in Table 1.

Table 1

Step	Reagent	Time (min)	Number of operations
Deprotection of Boc	HCl / DCM*	60	1
Washing	DCM	2 - 4	3
Neutralisation	10% DIPEA / DCM	4	2
Washing	DCM	2 - 4	1
Coupling	Activated ester	60 - 120**	1 - 2
Washing	DCM	2 - 4	3

\* Gaseous hydrogen chloride was bubbled through a suspension of the resin in DCM

\*\* Completeness of reaction was determined by a negative ninhydrin test

Benzotriazolyl esters were used as the activated esters throughout the synthesis. These were prepared from the corresponding protected amino acids by reaction with 1-

hydroxybenzotriazole (1eq.) and dicyclohexylcarbodiimide (1eq.). The quantities used (in relation to the resin substitution capacity) are listed in Table 2.


Table 2

Cycle no.	Amino acid derivative	Molar excess
1	Boc-Pro-OH	1.8
2	Boc-Tyr(Bzl)-OH	1.8
3	Boc-Trp(CHO)-OH	1.8
4	Boc-Gly-OH	1.8
5	Boc-His(Bom)-OH	1.8
6	Boc-Ser(Bzl)-OH	2.0
7	Boc-Trp(CHO)-OH	2.0
8	Boc- His(Bom)-OH	2.0
9	pyroGlu-OH	2.0

Following the final coupling, the resin was washed with dichloromethane (3 x 3L) and dried under reduced pressure at +40°C to constant weight.

Amino acid analysis: Consistent with proposed sequence

#### 1B. Cleavage and deprotection



The peptidoresin prepared in Example 1A was placed in a linen bag in a pressure vessel. The vessel was then charged with gaseous ammonia to a final pressure of 4atm. After 72h the excess ammonia was vented and the resin was extracted with acetic acid (3x100mL) and ethanol (3x100mL). The combined extracts were degassed with nitrogen, 10% palladium-on-carbon was added, and the mixture was stirred under an atmosphere of hydrogen. When the reaction was complete (as judged by HPLC), the mixture was filtered and the filtrate was evaporated. The residue was purified by reverse-phase HPLC to give the title compound.

**Example 2 - Analysis of the effects of GnRH-II and analogues on Osteogenic cell populations *in vitro*.**

(a) Human osteoblasts were isolated from cancerous bone from orthopaedic surgery (Nilsson *et al.*, 1995) according to standard procedures known in the art. The bone explants were minced into small bone chips and then washed extensively in Dulbecco's modified Eagle's medium (DMEM)/F12 (1:1 Gibco, Paisley, U.K). These osteoblast like cells, Murine osteoblastic MC3T3-E1 cells and human clonal osteosarcoma cell lines MG-63 (non-mineralising) and SaOS-2 (mineralising osteosarcoma) were cultured in DMEM:F12, 1:1 with the addition of 10% fetal calf serum (FCS, Gibco), fungizone (500mg/l), gentamycin sulphate (50mg/l), L-glutamine (2mM) and L-ascorbic acid (100mg/l) in a humidified CO<sub>2</sub> chamber at 37°C.

(b) Human bone marrow stromal cells were isolated from bone fragments rinsed in phosphate-buffered saline. Bone marrow cells were collected and spun through a column of Ficoll Hypaque (Kimble *et al* *J. Clin. Invest.* 93 1959-1967, 1994). Cells at the interface were pelleted, counted and seeded into 75cm<sup>2</sup> flasks. The cells were incubated in a humidified CO<sub>2</sub> chamber at 37°C and the medium changed weekly. At confluence, the cells were harvested using trypsin EDTA and re-seeded in α-minimum essential medium (α-MEM) supplemented with 10% fetal calf serum (FCS, Gibco), penicillin (100U/ml), streptomycin (100mg/ml), fungizone and L-glutamine (2mM).

(c) All cells were serum-starved for 48h before addition of GnRH-I and GnRH-II. Cells were placed in DMEM without phenol red (in order to avoid oestrogen-like effects of phenol red) containing 10% charcoal-stripped serum for 48h in 12 well plates. Dose dependent effects of GnRH-I and GnRH-II and analogues of the peptides were studied following the addition of peptides at final concentrations ranging from 10<sup>9</sup> to 10<sup>-6</sup>M. 1mM dibutyryl cAMP was used as a control. The cells were incubated for 24, 48 and 96h with the peptide being replaced every 24h.

(d) To assess the effects of the peptides on cell proliferation, [<sup>3</sup>H]thymidine was added at 1mCi/ml for an additional 24h and [<sup>3</sup>H]thymidine incorporation was determined. Radioisotope incorporation was determined using a scintillation counter and the results were calculated as cpm/mg of total protein.

(e) Expression of osteoblastic differentiation markers was also determined (Tintut Y et al., J Biol Chem 273 7547-53, 1998). Total RNA was isolated at several stages before treatment, at 24, 48, 72 and 96h after addition of peptides. Type I procollagen, osteopontin and 28S RNA (used as an internal control) expression was determined by Northern blot analyses. Alkaline phosphatase, matrix GLA protein, osteoclastin and GAPDH (as an internal control) were determined by RT-PCR with specific primers designed for each gene.

The peptides of the invention caused significant effects at concentrations below 100 $\mu$ M.

**Example 3 - Analysis of the effects of GnRH-II and analogues on Osteoclast populations *in vitro*.**

(a) Human clonal cell lines of osteoclast precursors (FLG 29.1) were used as an *in vitro* model of osteoclast differentiation (Gattei V et al., Cell Growth Differ 7 753-63, 1996). In addition, co-cultures of FLG 29.1 and osteoblastic cells (Saos-2) were evaluated for migratory, adhesive, cytochemical, morphological, and biochemical changes. Dose dependent effects of GnRH-I and GnRH-II and analogues of the peptides were studied following addition at final concentrations ranging from 10<sup>-9</sup> to 10<sup>-6</sup>M to FLG 29.1 cultures and to co-cultures. Parathyroid hormone was added as a control. Potentiation (or inhibition) of the differentiation of the preosteoclasts (fusion into large multinucleated elements) and a number of other factors were measured (Orlandini et al., Cell Tissue Res. 281 33-42, 1995). These included:

1. Positive staining for tartrate-resistant acid phosphatase in FLG 29.1 cells
2. A decrease of the alkaline phosphatase activity expressed by Saos-2 cells
3. The appearance of typical ultrastructural features of mature osteoclasts in FLG 29.1 cells
4. The release into the culture medium of granulocyte-macrophage colony stimulating factor.
5. To assess the effects the peptides on cell proliferation, [<sup>3</sup>H]thymidine was added at 1mCi/ml for an additional 24h and [<sup>3</sup>H]thymidine incorporation was determined as described above.

(b) Bone marrow cells removed from human bone fragments were cultured in the presence of 10nM 1,25-(OH)<sub>2</sub> vitamin D<sub>3</sub> for seven days to generate multinucleated osteoclasts using standard techniques known in the art (Takahashi et al., Endocrinol 122 1473-1482, 1988).

The culture medium ( $\alpha$ -MEM) was removed and replaced by a fresh phenol red free medium supplemented with antibiotics and 10% charcoal-stripped heat-inactivated FCS containing GnRH-I, GnRH-II or analogues, and the cultures were maintained for a further 24h. Floating cells were harvested and osteoclasts stained for tartrate-resistant acid phosphatase (TRAP) expression, a marker of osteoclast differentiation (Hughes *et al.*, *Nat. Med.* 2 1132-1135, 1996)

1. Cells were incubated in 0.2M acetate buffer, pH 4.7-5.0, containing tartaric acid and 2% naphthol AS-Bl phosphate (dissolved at 20mg/ml in ethylene glycol monomethyl ether) for 15min at 37°C. The cells were then transferred to a second solution consisting of the same buffer and concentration of tartaric acid with 0.1% pararosaniline chloride (hexazotised by mixing with an equal volume of 4% sodium nitrite for 5min at room temperature) for 10min at 37°C. This treatment causes a red cytoplasmic stain in cells expressing TRAP. Harris' hematoxylin was used as a nuclear counterstain.
2. Apoptotic multinucleated osteoclasts were identified by strong expression of TRAP, larger size than accompanying viable TRAP-positive cells. Confirmation of apoptosis was carried out using acridine orange stain. Viable osteoclasts were counted after fixation in 95% ethanol and TRAP hematoxylin staining, and apoptotic osteoclasts were expressed as a percentage of the total number of multinucleated osteoclasts (viable and apoptotic) in each culture well.

The peptides of the invention caused significant effects at concentrations below 100 $\mu$ M.

#### **Example 4- Expression analysis of GnRH mRNA in osteogenic and osteoclast cell populations**

Total RNA was extracted from cells cultured as described above:

1. osteoblast like cells, isolated from cancerous bone
2. murine osteoblastic MC3T3-E1 cells
3. MG-63 (non-mineralising)
4. SaOS-2 (mineralising osteosarcoma)
5. human bone marrow stromal cells
6. human FLG 29.1 osteoclast precursor cells
7. multinucleated osteoclasts generated from bone marrow

Expression of GnRH-I and GnRH-II was determined by RT-PCR using PCR primers outlined in SEQ 1.D. No 1-4. The integrity of the cDNA generated was determined by assessing the relative level of actin amplification.

**Example 5 - Effect of GnRH-II on bone mineral density in the ovariectomised rat**

(a) Female adult (8 weeks old, 200-215g) Sprague Dawley rats were bilaterally ovariectomised (OVX). Animals were kept for 4 weeks post-delivery before commencing treatment. Purina rat chow (1.00% calcium, 0.61% phosphorous) and water were provided ad libitum. Each study consisted of 6 weight-matched groups (n = 8/group).

(b) Treatment started 4 weeks post-OVX. After 4 weeks, a baseline control OVX group was sacrificed (Group A). The remaining groups were injected once a day with vehicle (Group B), 1 $\mu$ g/kg body weight (Group C), 10 $\mu$ g/kg body weight (Group D), 100 $\mu$ g/kg body weight (Group E) of GnRH-II, and 80 $\mu$ g/kg body weight (Group F) of hPTH(1-34).

(c) All rats were weighed every fourth day and dosages adjusted for 50g increase in mean group weight. Rats were given alternate subcutaneous injections of calcein (30mg/kg) or tetracyclin (30mg/kg) in 2% sodium bicarbonate-saline, respectively to label mineralization surfaces on days 10, 19 and 26, following treatment with drug. Bone mineral density was assessed by dual energy x-ray absorptometry-DEXA). On day 28 serum calcium levels were determined by colorimetric assay using a commercial kit.

(d) Success of OVX was confirmed at necropsy by failure to detect ovarian tissue and by observation of marked atrophy of the uterine horns. Both legs were disarticulated at the hip. The left tibia and femur were cleaned of excess muscle and soft tissue and placed in 70% ethanol. The anterior eminence of the right tibia metaphysis was shaved with a razor blade, barely exposing bone marrow. Both right femur and tibia were then placed in 10% phosphate-buffered formalin for 24h and transferred to 70% ethanol.

Ovariectomised animals treated daily with 10 and 100 $\mu$ g/kg of GnRH-II and 80 $\mu$ g/kg PTH for 28 days have pronounced hypercalcemia. Results are shown in Figure 1.

**Example 6 - Cellular localisation of GnRH-II in paraffin sections of normal rat bone and human bone.**

(a) Frozen and/or paraffin-embedded human and rat bone sections were fixed for 3-36h depending on size (3-5h at room temperature, then approx 24h at 4°C) and then soaked in 0.1M Tris + 5 % EDTA (12.11g + 50g EDTA) pH 7.3 until decalcified.

(b) Sections were then processed for antibody staining (rabbit polyclonal anti-GnRH-II antibody) using standard techniques.

Staining for GnRH-II was observed in platelets, megakaryocytes at the growth plate (especially proliferating chondrocytes). Some staining was also seen in the bone-forming cells particularly in active osteoblasts as well as new osteoid.

Overall, these results demonstrate that GnRH-II has a role in bone growth and calcium metabolism. Accordingly, it is useful as a therapeutic agent in diseases that are related to inadequate bone growth or loss of bone tissue.

## SEQUENCE LISTING

## INFORMATION FOR SEQ ID No 1.

## (i) Sequence Characteristics

- (a) Length: 19 bases
- (b) Type: nucleic acid
- (c) Strandedness: single
- (d) Topology: linear

## (ii) Molecule Type cDNA

## (iii) Sequence description: SEQ ID No.1

(1)

CTG CAG CTG CCT GAA GGA G

## INFORMATION FOR SEQ ID No 2.

## (i) Sequence Characteristics

- (a) Length: 19 bases
- (b) Type: nucleic acid
- (c) Strandedness: single
- (d) Topology: linear

## (ii) Molecule Type cDNA

## (iii) Sequence description: SEQ ID No.2

(2)

GGG CGG GGC GGG GCT CTC G

## INFORMATION FOR SEQ ID No 3.

## (i) Sequence Characteristics

- (a) Length: 21 bases
- (b) Type: nucleic acid
- (c) Strandedness: single
- (d) Topology: linear

## (ii) Molecule Type cDNA

## (iii) Sequence description: SEQ ID No.3

(3)

ATT CTA CTG ACT TGG TGC GTG

## INFORMATION FOR SEQ ID No 4.

## (i) Sequence Characteristics

- (a) Length: 21 bases
- (b) Type: nucleic acid
- (c) Strandedness: single
- (d) Topology: linear

## (ii) Molecule Type cDNA

## (iii) Sequence description: SEQ ID No.4

GGA ATA TGT GCA ACT TGG TGT

(4)

## CLAIMS

1. A pharmaceutical composition for the treatment of osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, and other disorders of bone metabolism, or for accelerating bone growth or repair, which composition is characterised by the inclusion of a peptide

pyroGlu-His-Trp-Ser-Xaa<sup>1</sup>-Gly-Xaa<sup>2</sup>-Xaa<sup>3</sup>-Pro-Gly-NH<sub>2</sub> (7)

or a salt thereof

wherein Xaa<sup>1</sup> is His or Tyr,  
Xaa<sup>2</sup> is Trp or Leu, and  
Xaa<sup>3</sup> is Tyr or Arg.

provided that when Xaa<sup>1</sup> is Tyr and Xaa<sup>2</sup> is Leu, then Xaa<sup>3</sup> is not Arg.

2. The composition according to Claim 1, wherein the composition is used for the treatment of osteoporosis.
3. The pharmaceutical composition according to Claim 1, wherein the peptide is

pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub> (6)

4. The composition according to Claim 3, wherein the composition is used for the treatment of osteoporosis.
5. A method of preparing a pharmaceutical composition for the treatment of osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, or another disorder of bone growth, which method comprises the mixing of a peptide according to the sequence

pyroGlu-His-Trp-Ser-Xaa<sup>1</sup>-Gly-Xaa<sup>2</sup>-Xaa<sup>3</sup>-Pro-Gly-NH<sub>2</sub> (7)

or a salt thereof

wherein Xaa<sup>1</sup> is His or Tyr,  
Xaa<sup>2</sup> is Trp or Leu, and  
Xaa<sup>3</sup> is Tyr or Arg.

provided that when Xaa<sup>1</sup> is Tyr and Xaa<sup>2</sup> is Leu, then Xaa<sup>3</sup> is not Arg, with one or more pharmaceutically acceptable excipients.

6. The method of Claim 5, wherein the composition is for the treatment of osteoporosis.

7. The method of Claim 5, wherein the peptide is

pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub> (6)

8. A method of treatment of an individual suffering from osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, or another disorder of bone growth, or at risk of so suffering, which comprises the administration to said individual of a therapeutically effective amount of a pharmaceutical composition which includes a peptide according to the sequence

pyroGlu-His-Trp-Ser-Xaa<sup>1</sup>-Gly-Xaa<sup>2</sup>-Xaa<sup>3</sup>-Pro-Gly-NH<sub>2</sub> (7)

or a salt thereof

wherein Xaa<sup>1</sup> is His or Tyr,  
Xaa<sup>2</sup> is Trp or Leu, and  
Xaa<sup>3</sup> is Tyr or Arg.

provided that when  $Xaa^1$  is Tyr and  $Xaa^2$  is Leu, then  $Xaa^3$  is not Arg, as an active principal.

9. The method of Claim 8, wherein the disorder of bone growth is osteoporosis.

10. The method of Claim 8, wherein the peptide is

pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub> (6)

## 11. A new use for a peptide according to the sequence

pyroGlu-His-Trp-Ser-Xaa<sup>1</sup>-Gly-Xaa<sup>2</sup>-Xaa<sup>3</sup>-Pro-Gly-NH<sub>2</sub> . . . (7)

or a salt thereof

wherein Xaa<sup>1</sup> is His or Tyr,  
 Xaa<sup>2</sup> is Trp or Leu, and  
 Xaa<sup>3</sup> is Tyr or Arg,

provided that when  $Xaa^1$  is Tyr and  $Xaa^2$  is Leu, then  $Xaa^3$  is not Arg.

which use is as a therapeutic agent for the treatment of osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, and other disorders of bone growth.

## 12. A new use for a peptide according to the sequence

pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub> (6)

which use is as a therapeutic agent for the treatment of osteoporosis and other disorders of bone growth.

1/1




Figure 1

# INTERNATIONAL SEARCH REPORT

Internat	Application No
PCT/GB 99/03553	

A. CLASSIFICATION OF SUBJECT MATTER	IPC 7 C07K7/23 A61K38/09 A61P19/10
-------------------------------------	------------------------------------

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 540 513 A (MIYAMOTO KAORU) 10 September 1985 (1985-09-10) abstract ---	1-12
Y	US 4 721 775 A (FOLKERS KARL ET AL) 26 January 1988 (1988-01-26) cited in the application column 3, line 30 - line 50 ---	1-12
Y	US 5 091 367 A (KOLAR CENEK ET AL) 25 February 1992 (1992-02-25) column 7 -column 8 ---	1-12
Y	WO 91 05563 A (UNIV TULANE) 2 May 1991 (1991-05-02) page 6, line 15 ---	1-12 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

4 February 2000

17/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

## INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/GB 99/03553

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US</p> <p>PAOLETTI A M ET AL.: "SPONTANEOUS REVERSIBILITY OF BONE LOSS INDUCED BY GONADOTROPIN - RELEASING HORMONE ANALOG TREATMENT" retrieved from STN XP002129776 abstract &amp; FERTILITY AND STERILITY (1996 APR) 65 (4) 707-10, -----</p>	

**INTERNATIONAL SEARCH REPORT**

International Application No

PCT/GB 99/03553

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 4540513	A 10-09-1985	NONE		
US 4721775	A 26-01-1988	NONE		
US 5091367	A 25-02-1992	DE 3634435 A	14-04-1988	
		AT 70278 T	15-12-1991	
		AU 595383 B	29-03-1990	
		AU 7945987 A	14-04-1988	
		CA 1314656 A	16-03-1993	
		DE 3775156 A	23-01-1992	
		DK 527187 A	10-04-1988	
		EP 0263521 A	13-04-1988	
		ES 2055696 T	01-09-1994	
		FI 874401 A, B,	10-04-1988	
		GR 3003927 T	16-03-1993	
		IE 60296 B	29-06-1994	
		IL 84121 A	21-06-1992	
		JP 2573625 B	22-01-1997	
		JP 63096198 A	27-04-1988	
		KR 9613387 B	04-10-1996	
		NZ 222076 A	27-09-1989	
		PH 24731 A	01-10-1990	
		PT 85881 A, B	01-11-1987	
		SK 408491 A	11-07-1995	
WO 9105563	A 02-05-1991	US 5003011 A	26-03-1991	
		CA 2044137 A	14-04-1991	
		EP 0448687 A	02-10-1991	
		GR 90100752 A	20-03-1992	
		NO 912254 A	12-08-1991	
		PT 95596 A	13-09-1991	

1/1




Figure 1